Gland Pharma

Why is Gland Pharma Ltd falling/rising?

As of 07-Aug, Gland Pharma Ltd's stock price is 2,600.45, down 0.65%. Despite this decline, the company has shown strong financial performance and positive growth metrics, although concerns about its high valuation and minimal long-term profit growth persist.

As of 07-Aug, Gland Pharma Ltd's stock price is currently at 2,600.45, reflecting a decrease of 17.05 (-0.65%). Despite this decline, the stock has shown positive performance in the short and long term, with a 1-week increase of 3.84% and a year-to-date rise of 50.99%. The stock is also trading close to its 52-week high, just 0.73% away from Rs 2,634.<BR><BR>The company's strong financial performance, including a net-debt-free status and impressive quarterly results, has contributed to its overall positive outlook. For instance, the company reported a higher PAT of Rs 829.42 Cr and the highest net sales of Rs 1,742.79 Cr in the last quarter. Additionally, high institutional holdings at 39.18% indicate confidence from knowledgeable investors.<BR><BR>However, the current price drop may be attributed to the stock's very expensive valuation, with a Price to Book Value of 4.2, which is higher than its peers. Furthermore, the operating profit growth has been minimal at an annual rate of only 0.04% over the past five years, raising concerns about long-term growth potential. Despite generating a return of 32.87% over the past year, the stock's profits have increased by 49.6%, resulting in a PEG ratio of 0.8, which suggests that the stock may be overvalued.<BR><BR>In summary, while Gland Pharma Ltd has demonstrated strong performance metrics and investor interest, the recent price decline can be linked to its high valuation and concerns regarding long-term growth.

Which are the latest news on Gland Pharma?

What does Gland Pharma do?

Gland Pharma Ltd is a small-cap pharmaceutical company specializing in the development and manufacturing of pharmaceutical products, with net sales of ₹1,743 Cr and a net profit of ₹367 Cr for the quarter ending March 2026. It has a market cap of ₹38,409 Cr and key metrics include a P/E ratio of 36.00 and a dividend yield of 0.78%.

Overview:<BR>Gland Pharma Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the development and manufacturing of pharmaceutical products.<BR><BR>History:<BR>Gland Pharma Limited was incorporated in 1978 as Gland Pharma Private Limited and later renamed to Gland Pharma Limited in 1995. The latest quarterly results report net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,743 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 367 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 38,409 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 36.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.78%<BR>- Debt Equity: -0.30<BR>- Return on Equity: 10.09%<BR>- Price to Book: 3.65<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Gland Pharma?

As of 10th June, Gland Pharma Ltd has a market capitalization of 38,409.00 Cr, with recent net sales of 6,430.65 Cr and a net profit of 1,027.32 Cr.

As of 10th June, Gland Pharma Ltd has a market capitalization of 38,409.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Gland Pharma reported Net Sales of 6,430.65 Cr and a Net Profit of 1,027.32 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 9,150.74 Cr and Total Assets valued at 11,172.85 Cr.

Who are in the management team of Gland Pharma?

The management team of Gland Pharma includes Chairman Yiu Kwan Stanley Lau, Managing Director & CEO Srinivas Sadu, and several non-executive and independent directors, such as Qi Yu Chen, Udo Johannes Vetter, C S N Murthy, Essaji Goolam Vahanvati, Naina Lal Kidwai, Jia Ai (Allen) Zhang, and Yao Fang. They are responsible for guiding the company's strategic direction and operations.

The management team of Gland Pharma includes the following key individuals:<BR><BR>1. **Yiu Kwan Stanley Lau** - Chairman & Independent Director<BR>2. **Srinivas Sadu** - Managing Director & CEO<BR>3. **Qi Yu Chen** - Non-Executive & Non-Independent Director<BR>4. **Udo Johannes Vetter** - Non-Executive & Non-Independent Director<BR>5. **C S N Murthy** - Independent Director<BR>6. **Essaji Goolam Vahanvati** - Independent Director<BR>7. **Naina Lal Kidwai** - Independent Director<BR>8. **Jia Ai (Allen) Zhang** - Non-Executive & Non-Independent Director<BR>9. **Yao Fang** - Non-Executive & Non-Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Gland Pharma?

Gland Pharma's peers include Alkem Lab, Glenmark Pharma, Abbott India, Anthem Bioscienc, Ipca Labs, Ajanta Pharma, Glaxosmi. Pharma, J B Chemicals, and Emcure Pharma. Gland Pharma has a good management risk and capital structure, with a 1-year return of 41.31%, outperforming peers like Glenmark Pharma (31.72%) and Glaxosmi. Pharma (-36.01%).

Peers: Gland Pharma's peers include Alkem Lab, Glenmark Pharma, Abbott India, Anthem Bioscienc, Ipca Labs, Ajanta Pharma, Glaxosmi. Pharma, J B Chemicals &, Emcure Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Ajanta Pharma, and Glaxosmi. Pharma, while Good management risk is found at Alkem Lab, Glenmark Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, Emcure Pharma, and J B Chemicals &. Below Average growth is noted for Alkem Lab, Ipca Labs, Gland Pharma, Ajanta Pharma, and Glaxosmi. Pharma, while Average growth is seen at Glenmark Pharma and Abbott India, and Excellent growth is present at Anthem Bioscienc. Capital Structure is Excellent for Alkem Lab, Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, and J B Chemicals &, while Good capital structure is noted for Glenmark Pharma and Emcure Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Glenmark Pharma at 31.72%, while Glaxosmi. Pharma has the lowest at -36.01%. Gland Pharma's 1-year return is 41.31%, which is significantly higher than both. Additionally, peers with negative six-month returns include Glaxosmi. Pharma and Abbott India.

Should I buy, sell or hold Gland Pharma Ltd?

Are Gland Pharma Ltd latest results good or bad?

Gland Pharma Ltd's latest Q4 FY26 results are strong, with a net profit of ₹366.68 crores (up 96.57% year-on-year) and revenue growth of 22.31% to ₹1,742.79 crores, alongside improved operating and PAT margins. However, concerns about the sustainability of these margins remain, necessitating consistent performance to maintain investor confidence.

Gland Pharma Ltd's latest results for Q4 FY26 can be considered good overall. The company reported a net profit of ₹366.68 crores, which reflects a remarkable year-on-year growth of 96.57%. Additionally, revenue grew by 22.31% compared to the same quarter last year, reaching ₹1,742.79 crores. This indicates strong demand for its products, particularly in the injectable segment.<BR><BR>Moreover, the operating margin has improved significantly, reaching 29.44%, the highest in eight quarters, and the profit after tax (PAT) margin increased to 21.04%, marking a substantial year-on-year improvement. These metrics suggest that Gland Pharma is effectively managing its operations and benefiting from favorable market conditions.<BR><BR>However, there are some concerns regarding the sustainability of these elevated margins, as the company has historically experienced fluctuations in its operating margins. While the current performance is impressive, it will be essential for Gland Pharma to maintain these levels in the coming quarters to reinforce investor confidence and justify its premium valuation in the market.<BR><BR>In summary, while the latest results are strong and indicate a positive trajectory, the company must demonstrate consistency in performance to fully capitalize on this momentum.

Is Gland Pharma technically bullish or bearish?

As of December 4, 2025, Gland Pharma's technical trend is mildly bearish, supported by bearish MACD readings, Bollinger Bands, and underperformance against the Sensex, despite some mixed signals from KST and daily moving averages.

As of 4 December 2025, the technical trend for Gland Pharma has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly and monthly MACD readings, both indicating a bearish sentiment. The Bollinger Bands also reflect a bearish trend on both time frames. The KST shows a mixed signal with a bullish monthly reading but a mildly bearish weekly signal, while the Dow Theory and OBV both confirm a mildly bearish outlook. The daily moving averages are mildly bullish, but this is overshadowed by the overall bearish indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish stance.

How has been the historical performance of Gland Pharma?

Gland Pharma's historical performance shows fluctuating financial metrics, with net sales and profits declining from March 2024 to March 2025, despite an increase in total assets. The company experienced a significant recovery in net cash inflow, contrasting with previous outflows.

Answer:<BR>The historical performance of Gland Pharma shows a fluctuating trend in key financial metrics over the past six years.<BR><BR>Breakdown:<BR>Gland Pharma's net sales peaked at 5,664.72 Cr in March 2024 but slightly decreased to 5,616.50 Cr in March 2025. The total operating income followed a similar pattern, reaching 5,664.72 Cr in March 2024 and then declining to 5,616.50 Cr in March 2025. The company's operating profit (PBDIT) also saw a decrease from 1,503.31 Cr in March 2024 to 1,482.53 Cr in March 2025. Profit before tax was 1,062.66 Cr in March 2025, down from 1,132.54 Cr in March 2024, while profit after tax decreased to 698.53 Cr from 772.46 Cr in the previous year. The earnings per share (EPS) fell from 46.90 in March 2024 to 42.39 in March 2025. On the balance sheet, total assets increased to 11,172.85 Cr in March 2025 from 10,610.81 Cr in March 2024, with total liabilities also rising to 11,172.85 Cr. The cash flow from operating activities decreased to 914 Cr in March 2025 from 996 Cr in March 2024, while the net cash inflow for March 2025 was 2,199 Cr, a significant recovery from the outflow of 1,551 Cr in March 2024. Overall, Gland Pharma's financial performance reflects a mix of growth in assets and fluctuations in profitability over the years.

Is Gland Pharma overvalued or undervalued?

As of November 7, 2025, Gland Pharma is considered overvalued with a PE ratio of 38.88, an EV to EBITDA of 4.16, and a PEG ratio of 2.72, indicating it is more expensive compared to peers like Sun Pharma and Cipla, and has underperformed the Sensex recently.

As of 7 November 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a shift in perception regarding its market worth. The company is currently considered overvalued. Key ratios include a PE ratio of 38.88, an EV to EBITDA of 4.16, and a Price to Book Value of 0.32, which suggest that while the company has a low book value relative to its market price, its earnings multiples are high compared to peers.<BR><BR>In comparison to its industry peers, Gland Pharma's PE ratio is higher than Sun Pharma's 35.17 and significantly higher than Cipla's attractive PE of 22.33. Additionally, the PEG ratio of 2.72 indicates that the stock may not be growing fast enough to justify its current price. Recent stock performance shows that Gland Pharma has underperformed the Sensex over the past week and month, which further supports the view that it is overvalued in the current market context.

Who are the top shareholders of the Gland Pharma?

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd. with 51.83%, mutual funds with 31.16%, and foreign institutional investors holding 6.9%. The largest public shareholder is Mirae Asset Large & Midcap Fund at 6.78%, while individual investors own 2.99%.

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd, which holds the largest stake at 51.83%. Additionally, mutual funds collectively hold 31.16% of the shares, with 24 different schemes involved. Among foreign institutional investors (FIIs), there are 163 holding 6.9% of the company. The highest public shareholder is Mirae Asset Large & Midcap Fund, which owns 6.78%. Individual investors account for 2.99% of the holdings.

When is the next results date for Gland Pharma?

No Upcoming Board Meetings

Has Gland Pharma declared dividend?

Yes, Gland Pharma has declared a dividend of 2000% (₹20 per share) with an ex-date of August 16, 2024. While the dividend yield is 1.23%, total returns have varied, showing negative performance in the short term but a strong positive return of 76.32% over the last two years.

Gland Pharma Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2000%<BR>- Amount per share: 20 per share<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 1.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.24%, the dividend return was 0%, resulting in a total return of -9.24%.<BR><BR>Over the past year, the price return was -10.71%, with a dividend return of 1.06%, leading to a total return of -9.65%.<BR><BR>For the 2-year period, the price return was 74.37%, the dividend return was 1.95%, resulting in a total return of 76.32%.<BR><BR>In the last 3 years, the price return was -42.39%, the dividend return was 0.77%, leading to a total return of -41.62%.<BR><BR>Over the past 4 years, the price return was -47.67%, with a dividend return of 0.62%, resulting in a total return of -47.05%.<BR><BR>In the last 5 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, Gland Pharma has declared a significant dividend, but the total returns over various periods show a mixed performance, with negative returns in the shorter terms and a strong positive return over the 2-year period.